Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
S100P is a useful marker for differentiation of ovarian mucinous tumors
Y. Umezaki1,*, M. Ito1, M. Nakashima2, Y. Mihara1, Y. Naruke1, H. Kurohama1, N. Yatsunami3, I. Yasuhi3
1 Department of Pathology, National Hospital Organization Nagasaki Medical Center, Nagasaki
1 Nagasaki University Graduate School of Biomedical Sciences, Nagasaki
2 Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute
3 Department of Obstetrics and Gynecology, National Hospital Organization Nagasaki Medical Center, Nagasaki (Japan)
Eur. J. Gynaecol. Oncol. 2015, 36(2), 131–137; https://doi.org/10.12892/ejgo2578.2015
Published: 10 April 2015
The S100P protein stimulates cell proliferation and survival, thereby contributing to tumor progression. The purpose of this study was to evaluate S100P expression in the three subtypes of mucinous cystic tumors, cystadenomas, borderline tumors, and adenocarcinomas. The authors examined nuclear S100P expression in 60 mucinous ovarian tumor specimens, including 24 specimens of mucinous cystadenoma, 15 of borderline tumors, and 21 of adenocarcinomas. Immunohistochemistry revealed S100P expression followed one of three patterns: (1) Expressed in most nuclei of mucinous epithelial cells, (2) sporadic (spotted or patchy) expression, or (3) absent or rarely expressed in the nuclei of mucinous epithelial cells. Most adenomas showed the first expression pattern, and borderline tumors often showed a patchy expression pattern. Adenocarcinomas generally demonstrated absence of S100P expression. These data suggest that S100P is a useful histological marker to differentiate between benign, borderline, and malignant mucinous tumors of the ovary.